Market Research and Industry Development Trend Report for Dermatological Drugs in China (2026–2032)

Table of Contents Chapter 1: Overview of the Dermatological Drugs Industry and Explanation of Data Sources 1.1 Definition of the Dermatological Drugs Industry 1.1.1 Definition of Dermatological Drugs 1.1.2 Differentiation of Similar Concepts 1.1.3 Classification of the Dermatological Drugs Industry under the "National Economic Industry Classification and Codes" 1.2 Common Symptoms and Classification of Skin Diseases 1.2.1 Common Symptoms of Skin Diseases 1.2.2 Product Classification of Skin Diseases 1.2.3 Pharmaceutical Classification of Skin Diseases 1.3 Regulatory Framework for the Dermatological Drugs Industry 1.3.1 Explanation of Professional Terminology in Dermatological Drugs 1.3.2 Introduction to the Regulatory System for Dermatological Drugs 1) Competent Authorities for the Dermatological Drugs Industry in China 2) Self-regulatory Organizations for the Dermatological Drugs Industry in China 1.3.3 Current Status of Standard System Construction for Dermatological Drugs 1) Standard System Construction for Dermatological Drugs in China 2) Summary of Existing Standards for Dermatological Drugs in China 3) Upcoming Standards for Dermatological Drugs in China 4) Interpretation of Key Standards for Dermatological Drugs in China 1.4 Scope Definition of This Report 1.5 Explanation of Data Sources and Statistical Criteria for This Report 1.5.1 Authoritative Data Sources for This Report 1.5.2 Explanation of Research Methodology and Statistical Criteria for This Report Chapter 2: Current Global Development Status and Future Trend Insights for the Dermatological Drugs Industry 2.1 Historical Development of the Global Dermatological Drugs Industry 2.2 Analysis of the Global Development Environment for Dermatological Drugs 2.2.1 Global Prevalence of Skin Diseases 2.2.2 Global Number of People Affected by Skin Diseases 2.3 Current Status Analysis of the Global Dermatological Drugs Industry 2.3.1 Analysis of Dermatological Drugs Under Development Globally 2.3.2 Analysis of the Global Market Size for Dermatological Drugs 2.4 Regional Development Patterns and In-depth Market Studies of Key Regions in the Global Dermatological Drugs Industry 2.4.1 Regional Development Patterns of the Global Dermatological Drugs Industry 2.4.2 Analysis of the U.S. Dermatological Drugs Market 1) Statistics on the Number of People with Skin Diseases 2) Analysis of Enterprises Participating in the Dermatological Drugs Market 2.4.3 Analysis of the European Dermatological Drugs Market 2.5 Competitive Landscape Analysis of the Global Dermatological Drugs Industry 2.5.1 Competitive Landscape of the Global Dermatological Drugs Industry 2.5.2 Mergers and Acquisitions Among Global Dermatological Drugs Enterprises 2.6 Forecast of Future Trends and Market Outlook for the Global Dermatological Drugs Industry 2.6.1 Forecast of Future Trends in the Global Dermatological Drugs Industry (e.g., Impact of Pandemics) 2.6.2 Market Outlook Forecast for the Global Dermatological Drugs Industry (Five-Year Data Forecast) 2.7 Lessons Learned from Global Dermatological Drugs Industry Development Chapter 3: Analysis of Supply-Demand Scale and Development Pain Points in China’s Dermatological Drugs Industry 3.1 Current Status of Technological Development in China’s Dermatological Drugs Industry 3.1.1 Analysis of Key Technologies in China’s Dermatological Drugs Industry 1) Innovative Drug Delivery Technologies for Dermatological Treatments 2) Innovative Therapeutic Approaches and Novel Targets for Respiratory Disease Treatments 3.1.2 R&D Investment Status in China’s Dermatological Drugs Industry (R&D Intensity and Effort) 3.1.3 Scientific Research Achievements in China’s Dermatological Drugs Industry (Patents, Technology Transfer, etc.) 1) Patent Applications in China’s Dermatological Drugs Industry 2) Patent Publications in China’s Dermatological Drugs Industry

IPOs Must Respect and Adhere to Market Rules

Recently, intense debate has arisen over whether IPOs should be suspended amid a stock market downturn. The necessity of suspending IPOs during a stock market downturn is a highly contentious topic. An IPO (Initial Public Offering) is the process through which a company raises capital by issuing shares to the public. It serves as a vital channel for corporate growth and expansion, as well as an opportunity for investors to earn returns. However, suspending IPOs during a market downturn may constitute a reasonable policy decision. A stock market downturn reflects weak investor confidence. When markets decline, investors become more cautious and skeptical toward newly listed companies. Conducting IPOs under such conditions may lead to falling share prices, thereby undermining companies’ fundraising plans and long-term development prospects. Suspending IPOs can mitigate this risk and safeguard the interests of both enterprises and investors. A market downturn may also destabilize the IPO market. Under unstable market conditions, investors tend to adopt conservative investment strategies, favoring mature companies with stable profitability. This reduces demand for newly listed stocks, potentially resulting in failed IPOs or significantly undersubscribed offerings. Thus, suspending IPOs helps avoid wasting time and resources for both companies and investors, while preserving overall market stability. A market downturn may also negatively impact company valuations. During bull markets, investors show greater enthusiasm for emerging industries and innovative firms, willing to assign them higher valuations. Conversely, during bear markets, investors prioritize risk control and return assurance, imposing stricter valuation requirements. Consequently, some companies may postpone or even abandon their IPO plans until market conditions improve. In mature Western securities markets—such as those in Europe and the United States—IPOs are largely self-regulated in accordance with market principles. During market downturns, the pace and volume of new share issuances decline sharply; conversely, they accelerate during upswings. Market signals—whether bearish or bullish—are transmitted directly to prospective listing companies, prompting them to voluntarily delay or withdraw their listing applications. This entire process is driven entirely by the inherent, self-regulating mechanisms of the securities market—a natural outcome of full marketization.

Leo Pharma Considers Postponing IPO Amid Market Turmoil

21 hours ago

Danish drugmaker Leo Pharma is considering delaying its planned IPO until 2027 due to ongoing global financial market turmoil. A company spokesperson declined to comment on the potential delay.

reuters

2026-11-06

Leo Pharma Considers Postponing IPO Amid Market Turmoil

Leo Pharma Considers Postponing IPO Amid Market Turmoil

FAQ